Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Favipiravir  COVID-19 treatment studies for Favipiravir  C19 studies: Favipiravir  Favipiravir   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Hospitalization 89% Improvement Relative Risk ER visit 30% Recovery -19% Viral shedding -32% primary c19early.org/a Holubar et al. Favipiravir for COVID-19 RCT EARLY Is early treatment with favipiravir beneficial for COVID-19? Double-blind RCT 149 patients in the USA Lower hospitalization (p=0.058) and progression (p=0.56), not stat. sig. Holubar et al., Clinical Infectious Diseases, doi:10.1093/cid/ciac312 Favors favipiravir Favors control
Favipiravir for treatment of outpatients with asymptomatic or uncomplicated COVID-19: a double-blind randomized, placebo-controlled, phase 2 trial
Holubar et al., Clinical Infectious Diseases, doi:10.1093/cid/ciac312 (date from earlier preprint)
Holubar et al., Favipiravir for treatment of outpatients with asymptomatic or uncomplicated COVID-19: a double-blind.., Clinical Infectious Diseases, doi:10.1093/cid/ciac312 (date from earlier preprint)
Nov 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Small RCT 116 mITT patients in the USA, 59 treated with favipiravir, showing no significant differences with treatment.
risk of hospitalization, 89.0% lower, RR 0.11, p = 0.06, treatment 0 of 75 (0.0%), control 4 of 74 (5.4%), NNT 18, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of ER visit, 29.5% lower, RR 0.70, p = 0.56, treatment 5 of 75 (6.7%), control 7 of 74 (9.5%), NNT 36.
risk of no recovery, 19.0% higher, RR 1.19, p = 0.43, treatment 65, control 70, inverted to make RR<1 favor treatment, initial resolution of symptoms.
viral shedding, 31.6% higher, RR 1.32, p = 0.24, treatment 59, control 57, inverted to make RR<1 favor treatment, primary outcome.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Holubar et al., 24 Nov 2021, Double Blind Randomized Controlled Trial, USA, peer-reviewed, 26 authors, average treatment delay 5.0 days, conflicts of interest: Pfizer, Gates Foundation, Gilead, Regeneron, Janssen.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperFavipiravirAll
Abstract: 2 a double-blind randomized, placebo-controlled, phase 2 trial 3 Marisa Holubar MD,1 Aruna Subramanian MD,1 Natasha Purington PhD,2 Haley Hedlin PhD,2 4 Bryan Bunning MS,2 Katharine S. Walter PhD,1 Hector Bonilla MD,1 Athanasia Boumis,3 5 Michael Chen MD,4 Kimberly Clinton,3 Liisa Dewhurst,3 Carol Epstein MD,5 Prasanna 6 Jagannathan MD,1,6 Richard H. Kaszynski MD,4 Lori Panu,3 Julie Parsonnet MD,1,7 Elizabeth L. 7 Ponder PhD,8 Orlando Quintero MD,1 Elizabeth Sefton PhD,8 Upinder Singh MD,1,6 Luke 8 Soberanis,3 Henry Truong PharmD,9 Jason R. Andrews MD,1 Manisha Desai PhD,2 Chaitan 9 Khosla PhD,10,8 Yvonne Maldonado MD11,7 10 1. 2. 13 N M Medicine, Stanford, CA, USA Quantitative Sciences Unit, Division of Biomedical Informatics Research, Department of D 12 Division of Infectious Diseases and Geographic Medicine, Stanford University School of A 11 U SC RI PT Favipiravir for treatment of outpatients with asymptomatic or uncomplicated COVID-19: Medicine, Stanford University, Palo Alto, CA, USA 3. Stanford Center for Clinical Research, Stanford University, Stanford, CA, USA 15 4. Stanford Solutions, Stanford University School of Medicine, Stanford, CA 94305, USA 16 5. Carol L. Epstein MD Consulting LLC, Wellington, FL, USA 17 6. Department of Microbiology and Immunology, Stanford University School of Medicine, 7. 20 21 EP Stanford, CA, USA A 19 CC 18 TE 14 8. Department of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, CA, USA Stanford ChEM-H, Stanford University, Stanford CA, USA © The Author(s) 2022. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons AttributionNonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits noncommercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com 1 1 1 9. Mariner Advanced Pharmacy Corp, San Mateo, California 2 10. Departments of Chemistry and Chemical Engineering, Stanford University, Stanford, 3 CA, USA 4 11. 5 Correspondence: 6 Marisa Holubar, MD MS 7 Clinical Associate Professor of Medicine 8 Division of Infectious Diseases and Geographic Medicine 9 Stanford University School of Medicine 10 300 Pasteur Drive, Lane Building 145 Stanford, CA 94305 USA 11 mholubar@stanford.edu U N A M D TE EP CC A 12 SC RI PT Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA 2 Background: Favipiravir is an oral, RNA-dependent RNA polymerase inhibitor with in vitro 3 activity against SARS-CoV2. Despite limited data, favipiravir is administered to patients with 4 COVID-19 in several countries. 5 Methods: We conducted a phase 2 double-blind randomized controlled outpatient trial of 6 favipiravir in asymptomatic or mildly symptomatic adults with a positive SARS-CoV2 RT-PCR 7 within 72 hours of enrollment. Participants were randomized 1:1 to receive placebo or favipiravir 8 (1800..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit